Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AI Therapeutics

AI Therapeutics
2013 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series C LATEST DEAL TYPE
$58M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of precision therapeutics technology designed to outsmart cancer and rare diseases. The company's technology accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics and combinational drug screening with deep learning to match clinical drugs, enabling doctors to treat Lymphangioleiomyomatosis by providing significant therapeutic benefit for patients.

Formerly Known As
LAM Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 530 Old Whitfield Street
  • Guilford, CT 06437
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AI Therapeutics’s full profile, request a free trial.

AI Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 30-Mar-2017 $58M 0000 00000 Completed Startup
3. Corporate (Series B) 03-Feb-2016 0000 0000 0000 Completed Startup
2. Early Stage VC (Series A) 06-Jun-2013 $20M $20M 0000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

AI Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 25,250,000 $0.000100 8% $0.8 $0.8 1x $0.8 30.53%
To view this company’s complete Cap Table, request access »

AI Therapeutics Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
0000000 0000000000 Formerly VC-backed Richmond, CA 000 000.00 00000000 000.00
0000000000 Venture Capital-Backed Abingdon, United Kingdom 000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

AI Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Yonghua Capital Venture Capital Minority 000 0000 000000 0
Xiphos Bio Corporation Minority 000 0000 000000 0
4Catalyzer Accelerator/Incubator Minority 000 0000 000000 0

AI Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Henri Lichenstein Ph.D President, CSO & Chief Executive Officer
Tian Xu Ph.D Co-Founder & Scientific Advisor
Paul Beckett Ph.D Senior Director of Drug Discovery
Jonathan Rothberg Ph.D Co-Founder & Board Member

AI Therapeutics Board Members (3)

Name Representing Role Since Contact
Info
George Rehm JD Self Board Member 000 0000
Gregg Fergus 4Catalyzer Board Member 000 0000
Jonathan Rothberg Ph.D Self Co-Founder & Board Member 000 0000